4004.SR
Bargain BinDallah Healthcare Company · Healthcare · Saudi Arabia · $1.9B cap · $3.2M/day traded
SAR 58.75 -0.4% · close 5 Nov · scored 7 Nov
Bargain Bin: Looks like a bargain; the quality and the trend say why it is in the bin.
As of 7 Nov 2026, the MoatMap Score for Dallah Healthcare Company (4004.SR) is 34/100, ranked against 25,000+ stocks in 38 markets (Quality 45, Value 53, Momentum 27, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT DALLAH HEALTHCARE COMPANY
Read
Dallah Healthcare Company operates as a health care company in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthcare facilities, medical centres, complexes, and clinics; and the provision of manpower and support services.
FINANCIAL SUMMARY (SAR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5B | 2.9B | 3.2B | 4.1B | 17.8% | 4.4B | 4.5B | 5.0B | 10.9% |
| EPS (SAR) | 3.05 | 3.70 | 4.83 | 5.32 | 20.4% | 3.73 | 5.98 | 5.64 | 3.0% |
| Shares | 90.0M | 97.7M | 97.3M | 101.1M | +12.3% | 121.9M | — | — | — |
| Debt | 2.0B | 2.0B | 2.0B | 3.9B | 25.8% | 4.4B | — | — | — |
| Equity | 2.0B | 3.2B | 3.5B | 4.1B | 27.1% | — | — | — | — |
| Op CF | 442.1M | 625.8M | 678.3M | 555.4M | 7.9% | 431.3M | — | — | — |
| Inv CF | -179.1M | -293.7M | -357.1M | -787.4M | — | — | — | — | — |
| Fin CF | -233.1M | -334.7M | -390.1M | 276.2M | — | — | — | — | — |
Made a new 52-week low 2 trading days ago, 53% below its 52-week high. The fall has not stopped yet.
Calmer than 66% of stocks we rank over the past year (volatility 33% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4004.SR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| 4004.SR | Dallah Healthcare Company(you) | $1.9B | 34 |
| 4017.SR | Dr. Soliman Abdel Kader Fakeeh Hospital Company | $1.9B | 42 |
| 4018.SR | Almoosa Health Company | $1.3B | 30 |
| 4005.SR | National Medical Care Company | $1.2B | 62 |
| 4007.SR | Al Hammadi Holding Company | $925M | 68 |
| 4019.SR | Specialized Medical Company | $875M | 69 |
| 4013.SR | Dr. Sulaiman Al Habib Medical Services Group Company | $20.1B | 45 |
| 4002.SR | Mouwasat Medical Services Company | $2.9B | 85 |
| 9627.SR | Twareat Medical Care Company | $96M | 30 |
| 4009.SR | Middle East Healthcare Company | $563M | 73 |
Peer medians: ROE 15.6% · P/E 16.2x · Gross margin 31.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.